np10679
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 6, 2018 (NCT03565861)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glutamate [NMDA] receptor subunit 3AALLOSTERIC ANTAGONIST
GRIN3A allosteric antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04007263 | Phase 1 | Apr 4, 2019 | National Institute of Neurological Disorders and Stroke (NINDS), Neurop Inc., Pharmaron |
| NCT03565861 | Phase 1 | Apr 6, 2018 | Neurop Inc., Pharmaron |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neurop Inc. | For profit | 2 | 2 | 1 | 2018 |
| Pharmaron | For profit | 2 | 0 | 1 | 2018 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1